Consistent with those findings, the results of our study indicated that AML cells with high TP53INP2 expression were more sensitive to TRAIL in vitro and in CDX mouse models and that the suppression of TP53INP2 expression significantly reduced vulnerability to TRAIL. This evidence concerns the gene TNFSF10 and acute myeloid leukemia.